drugset
drugset / Trial / NCT03824405

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

NCT03824405 ↗

Phase 2 Completed 200 enrolled Botanix Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.

Timeline

Start
2019-02-04
Primary completion
2020-01-27
Completion
2020-03-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cannabidiol Other / unclassified — —

Indications

atopic eczema